Formoterol-budesonide combination therapy for asthma does not increase adverse events : 2minutemedicine

as informed in 2minutemedicine

Formoterol-budesonide combination therapy for asthma does not increase adverse events

Formoterol-budesonide combination therapy for asthma does not increase adverse events

For patients with moderate-to-severe asthma, budesonide-formoterol combination therapy was not associated with a higher risk of serious asthma-related events than budesonide alone.Budesonide-formoterol combination therapy demonstrated superior efficacy compared to budesonide monotherapy.Evidence Rating Level: 1 (Excellent)Study Rundown: There is controversy regarding a possible association between the chronic use of long-term beta agonists (LABAs) and mortality in asthmatics.


in addition eurekalert

Study shows combination drug therapy for asthma patients is safe

Study shows combination drug therapy for asthma patients is safe

WINSTON-SALEM, N.C. - Sept. 1, 2016 - A post-marketing safety study mandated by the U.S. Food and Drug Administration has shown that a combination drug therapy for the treatment of asthma is safe and effective.The therapy tested consisted of a long-acting beta agonist, formoterol, added to an inhaled glucocorticoid, budesonide."Our study showed no significant increase in serious adverse events in the combination therapy," said Stephen Peters, M.D., Ph.D., professor of pulmonary, critical care, allergy and immunologic diseases at Wake Forest Baptist Medical Center and lead author of the study.


by the same token on medicalxpress

Study shows combination drug therapy for asthma patients is safe

Study shows combination drug therapy for asthma patients is safe

A post-marketing safety study mandated by the U.S. Food and Drug Administration has shown that a combination drug therapy for the treatment of asthma is safe and effective.The therapy tested consisted of a long-acting beta agonist, formoterol, added to an inhaled glucocorticoid, budesonide."Our study showed no significant increase in serious adverse events in the combination therapy," said Stephen Peters, M.D., Ph.D., professor of pulmonary, critical care, allergy and immunologic diseases at Wake Forest Baptist Medical Center and lead author of the study.